HIGHLIGHTS
- who: Hugo Jourdain from the total of, new or prevalent users from the date of first commercialization in FranceCru00e9teil University have published the paper: TNF-alpha inhibitors biosimilar use in France: a nationwide population-based study using the French National Health Data System, in the Journal: Rheumatology of January/27,/2015
- what: In this large descriptive study, including 102,445 initiating patients from biosimilar market entry and 104,673 prevalent patients at biosimilar market entry, the authors show that the level of penetration of TNF-alpha inhibitors` biosimilars varies greatly according to the molecule and . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.